Source comparison
NAD+ Dosage Protocol Guide: Administration Method Comparison
This table summarizes the key differences between NAD+ administration routes and their implications for research protocol design. | Administration Route | Bioavailability | Onset Time | Peak Plasma NAD+ | Effective Dose Range | Primary Use Case | Professional
This comparison does not assign a generated winner or score.
- This table summarizes the key differences between NAD+ administration routes and their implications for research protocol design.
- | Administration Route | Bioavailability | Onset Time | Peak Plasma NAD+ | Effective Dose Range | Primary Use Case | Professional Assessment ||—|—|—|—|—|—|| Intravenous (IV) | 100% | 5–10 minutes | 30 minutes post-infusion | 250–1000mg per session | Acute intervention studies requiring rapid NAD+ elevation; suitable for measuring immediate metabolic response | Highest bioavailability but also highest CD38 upregulation risk. Requires careful dose titration to prevent tolerance || Subcutaneous (SC) | 70–85% | 30–60 minutes | 2–4 hours post-injection | 50–200mg per injection | Sustained NAD+ elevation studies; mitochondrial function assays requiring stable levels over 4–6 hours | Optimal for research requiring consistent NAD+ levels without acute spikes. Lower CD38 activation compared to IV || Oral Precursors (NMN/NR) | 15–40% | 60–90 minutes | 3–6 hours post-dose | 250–500mg daily | Long-term studies measuring tissue-specific NAD+ synthesis; sirtuin activation protocols | Bypasses plasma